| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Wedelolactone (IKK Inhibitor II) is a naturally occuring coumarin ether with potent hepatoprotective activities. Wedelolactone Attenuates Pulmonary Fibrosis Partially Through Activating AMPK and Controlling Raf-MAPKs Signaling Pathway. Wedelolactone inhibits melanoma cell migration and proliferation by inhibiting AKT and AMPK signaling. Wedelolactone Enhances Odontoblast Differentiation by Enhancing Wnt/β-Catenin Signaling Pathway and Suppressing NF-κB Signaling Pathway.
| Targets |
5-LOX (IC50 = 2.5 μM); Caspase-11; Apoptosis
|
|---|---|
| ln Vitro |
Wedelolactone (0-5 μg/mL; 0-21 d) promotes osteoblast differentiation in bone marrow mesenchymal stem cells (BMSCs)[3].
Wedelolactone (0-6 μg/mL; 0-9 d) inhibits GSK3β activity, boosts nuclear accumulation of β-catenin and runx2 in BMSC, and inhibits the action of RANKL[3]. Wedelolactone 0-5 μg/ml; 60 min) inhibits GSK3β activity, demonstrating that GSK3β is the drug's target[3]. Wedelolactone (0-5 μg/ml; 6 d) inhibits the expression of c-src, c-fos, and cathepsin K[3]. |
| ln Vivo |
Wedelolactone (10 mg/kg; i.p. every 2 days for 4 weeks) reduces bone volume and trabecular number at the femur following ovariectomies and prevents VOX-induced bone loss[3].
|
| References |
|
| Additional Infomation |
Wedelolactone is a member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3. It has a role as an antineoplastic agent, an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor, an apoptosis inducer, a hepatoprotective agent and a metabolite. It is a member of coumestans, a delta-lactone, an aromatic ether and a polyphenol. It is functionally related to a coumestan.
Wedelolactone has been reported in Hypericum erectum, Aconitum kongboense, and other organisms with data available. |
| Molecular Formula |
C16H10O7
|
|---|---|
| Molecular Weight |
314.2464
|
| Exact Mass |
314.042
|
| Elemental Analysis |
C, 61.15; H, 3.21; O, 35.64
|
| CAS # |
524-12-9
|
| Related CAS # |
524-12-9
|
| PubChem CID |
5281813
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
498.4±45.0 °C at 760 mmHg
|
| Melting Point |
315 °C
|
| Flash Point |
255.2±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.759
|
| LogP |
2.75
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
483
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2=C([H])C(=C(C([H])=C2C2C(=O)OC3=C([H])C(=C([H])C(=C3C1=2)O[H])OC([H])([H])[H])O[H])O[H]
|
| InChi Key |
XQDCKJKKMFWXGB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H10O7/c1-21-6-2-10(19)14-12(3-6)23-16(20)13-7-4-8(17)9(18)5-11(7)22-15(13)14/h2-5,17-19H,1H3
|
| Chemical Name |
1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one
|
| Synonyms |
IKK Inhibitor II; Wedelolactone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 63~125 mg/mL (200.5~397.8 mM)
Ethanol: ~1.5 mg/mL (~4.8mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1822 mL | 15.9109 mL | 31.8218 mL | |
| 5 mM | 0.6364 mL | 3.1822 mL | 6.3644 mL | |
| 10 mM | 0.3182 mL | 1.5911 mL | 3.1822 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
